Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.

Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications

Open access
Zhang, Xinyu, Cao, Chao, Zheng, Fei, Liu, Chang, Tian, Xiuqing · 2026 · Cardiovascular Drugs and Therapy

Abstract

BACKGROUND: Glucagon-like peptide-1 (GLP-1) is a crucial incretin hormone secreted by intestinal endocrine L cells. Given its pivotal physiological role, researchers have developed GLP-1 receptor agonists (GLP-1 RAs) through structural modifications. These analogues display pharmacological effects similar to those of GLP-1 but with augmented stability and are regarded as an effective means of regulating blood glucose levels in clinical practice. OBJECTIVE: This review aims to comprehensively summarize the role of GLP-1 RAs in the management of diabetes mellitus (DM) and cardiovascular disease (CVD), with a particular emphasis on the underlying signal transduction pathways and their therapeutic potential. METHODS: A comprehensive review was carried out through literature research. RESULTS AND DISCUSSION: In pancreatic β-cells, GLP-1 RAs regulate the secretion of insulin and glucagon in a glucosedependent manner by influencing signaling pathways such as cAMP, PI3K, and MAPK. They also contribute to the regulation of blood glucose levels by promoting the proliferation of β-cells and inhibiting apoptosis in these cells. Recent comprehensive studies have also demonstrated the favorable impact of GLP-1 RAs on cardiovascular wellbeing. In addition to the cardiovascular protection afforded by glucose metabolism regulation, a large body of evidence from animal and cellular studies has corroborated the beneficial effects of GLP-1 RAs on conditions such as heart failure (HF), hypertension, and ischemic cardiomyopathy. These benefits are mainly attributed to the alleviation of inflammatory responses, reduction of oxidative stress, and prevention of cell apoptosis. Clinical data shows that GLP-1 RAs can reduce the risk of major adverse cardiovascular events (MACE) in diabetic patients. CONCLUSION: GLP-1 RAs play an important role in the management of both diabetes and cardiovascular diseases. They show potential therapeutic value through the modulation of multiple signal transduction pathways. However, there may still be some issues in practical applications that require further research and resolution.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10557-025-07670-9

Cites

107 of 107 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 GLP-1 RAs
Fig. 1 GLP-1 RAsCC BY-NC-ND · PubMed Central
Fig. 2 PKCζ, a PI3K effector, is essential for β-cell proliferation and differentiation
Fig. 2 PKCζ, a PI3K effector, is essential for β-cell proliferation and differentiationCC BY-NC-ND · PubMed Central
Fig. 3 GLP-1 RAs such as exenatide and liraglutide modulate signaling pathways to reduce oxidative stress, reactive oxygen species (ROS) production, and apoptosis
Fig. 3 GLP-1 RAs such as exenatide and liraglutide modulate signaling pathways to reduce oxidative stress, reactive oxygen species (ROS) production, and apoptosisCC BY-NC-ND · PubMed Central
Fig. 4 Liraglutide was demonstrated to inhibit NLRP3 inflammasome-induced pyroptosis in ischemia–reperfusion rats
Fig. 4 Liraglutide was demonstrated to inhibit NLRP3 inflammasome-induced pyroptosis in ischemia–reperfusion ratsCC BY-NC-ND · PubMed Central
Fig. 5 GLP-1 RAs have been demonstrated to effectively support cardiomyocyte survival by addressing a number of key mechanisms
Fig. 5 GLP-1 RAs have been demonstrated to effectively support cardiomyocyte survival by addressing a number of key mechanismsCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 107 references

Cited by

See all 27

Metadata

Authors
Zhang, X., Cao, C., Zheng, F., Liu, C., & Tian, X.
Affiliations
Shandong Provincial QianFoShan Hospital (CN)
Corresponding author
Tian, Xiuqing
Venue
Cardiovascular Drugs and Therapy
Published
2025-01-20
Volume
40
Issue
1
Pages
287-301
ISSN
  • 0920-3206 (ISSN-L)
  • 1573-7241
OpenAlex
W4406598762
Cited by
27
References
107
Citations by year
2026: 15 · 2025: 12
FWCI
3.67
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Drugs and Therapy (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
Funders
  • Natural Science Foundation of Shandong Province (Grant No. ZR2021MH039, Grant No. 8217021865)
  • Clinical Science and Technology Innovation Program (Grant No.202019089)
  • Major Project of Shandong University (Grant No. qlyxjy-201830)
  • Project of Shandong Provincial Medical Association (Grant No. YXH2024YS039)
  • Research Fund of Qianfoshan Hospital (Grant No. QYPY2021NSFC0619)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
GLP-1 receptor agonists, glucagon-like peptide-1, diabetes mellitus, cardiovascular disease, incretin signaling, beta-cell function, insulin secretion, glucagon secretion, signaling pathways, cyclic AMP, phosphatidylinositol 3-kinase, mitogen-activated protein kinase, beta-cell proliferation, beta-cell apoptosis, heart failure, hypertension, ischemic cardiomyopathy, major adverse cardiovascular events, oxidative stress, inflammation
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Humans, Hypoglycemic Agents, Signal Transduction, Treatment Outcome, Insulin-Secreting Cells, Glucagon-Like Peptide 1, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications. https://app.cochat.ai/papers/10.1007/s10557-025-07670-9
The paper
Zhang, X., Cao, C., Zheng, F., Liu, C., & Tian, X. (2026). Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-025-07670-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.